Spots Global Cancer Trial Database for A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
Official Title: A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
Study ID: NCT04875806
Interventions
Study Description
Brief Summary: This research study is studying a new drug, NC762, as a possible treatment for advanced or metastatic solid tumors.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Yale Cancer Center, New Haven, Connecticut, United States
The University of Chicago Medicine and Biological Sciences, Chicago, Illinois, United States
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
Carolina BioOncology Institute, Huntersville, North Carolina, United States
Gettysburg Cancer Center, Gettysburg, Pennsylvania, United States
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Inova Schar Cancer Institute, Fairfax, Virginia, United States
Contact Details
Name: Han Myint, MD
Affiliation: NextCure, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
